You are here: Industry Insights > HIV

News List

Trump administration block NIH researchers from using foetal tissue, disrupting research to cure HIV pharmafile
December 11, 2018
The Trump Administration has halted the acquisition of new human foetal tissue for use in experiments conducted by NIH researchers, thus disrupting research into a cure for HIV.
Gene-edited Babies Immune to HIV: A Discussion about “CRISPR-Cas9” and “CCR5” 1℃
December 05, 2018
This is the world’s first case of gene-edited babies immune to HIV, and shows a historic breakthrough of China in the field of genome editing technique for disease prevention.”
J&J touts new immune response data for HIV vaccine fiercepharma
December 04, 2018
Johnson & Johnson has already advanced a “mosaic” HIV vaccine candidate into efficacy testing in five southern African countries...
80 adolescents a day will still die of AIDS by 2030, despite slowdown in epidemic: UN biospectrumasia
December 03, 2018
Currently, 3 million persons 19 years and younger, are infected with HIV worldwide
HIV drug reduces viral load by 99% within 4 weeks pharmafile
November 20, 2018
HIV-drug Gammora may eliminate 99% of the HIV virus within four weeks of treatment, according to the results of a Phase 1/2a clinical trial, conducted by Israeli biotech Zion Medical.
Zydus Cadila gets US FDA nod to market generic HIV treatment tabs expressbpd
November 19, 2018
The product will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad
J&J touts latest immune response data for 'mosaic' HIV vaccine program fiercepharma
November 09, 2018
Johnson & Johnson has already advanced a “mosaic” HIV vaccine candidate into efficacy testing in five southern African countries, but this week the company unveiled initial
Johnson & Johnson steps up vaccines R&D—and prepares for launches—with €72M plant fiercepharma
November 09, 2018
Johnson & Johnson has big ambitions in vaccines, and to get there, its manufacturing has to measure up. The small plant acquired in its Crucell purchase just won't support...
ViiV’s fostemsavir shows promise in ‘heavily pre-treated’ HIV patients pharmatimes
November 05, 2018
ViiV Healthcare’s first-in-class attachment inhibitor fostemsavir has shown promise as a treatment for heavily pre-treated HIV patients failing on...
GSK announces two sets of positive results for HIV treatments pharmaceutical-technology
November 02, 2018
GlaxoSmithKline (GSK)’s human immunodeficiency virus (HIV) business ViiV Healthcare has announced positive results for two treatments for the virus.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 24 25 Next page